Novo Nordisk A/S (NVO) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 29, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2025, filed Feb 4, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the NVO SEC filings page.
Novo Nordisk A/S (NVO) reported $48.6B in revenue for fiscal year 2025, up 20.5% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Novo Nordisk A/S's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Novo Nordisk A/S has an operating margin of 41.3%, meaning the company retains $41 of operating profit per $100 of revenue. This strong profitability earns a score of 97/100, reflecting efficient cost management and pricing power. This is down from 44.2% the prior year.
Novo Nordisk A/S's revenue surged 20.5% year-over-year to $48.6B, reflecting rapid business expansion. This strong growth earns a score of 80/100.
Novo Nordisk A/S has a moderate D/E ratio of 1.19. This balance of debt and equity financing earns a leverage score of 40/100.
Novo Nordisk A/S's current ratio of 0.80 is below the typical benchmark, resulting in a score of 12/100. This tight liquidity could limit financial flexibility if cash inflows slow.
Novo Nordisk A/S converts 19.1% of revenue into free cash flow ($9.3B). This strong cash generation earns a score of 90/100.
Novo Nordisk A/S earns a strong 52.8% return on equity (ROE), meaning it generates $53 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 94/100. This is down from 70.4% the prior year.
Novo Nordisk A/S scores 3.64, well above the 2.99 safe threshold. The largest contribution to the score comes from a market capitalization of $172.6B against total liabilities of $54.8B. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Novo Nordisk A/S passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Novo Nordisk A/S generates $1.16 in operating cash flow ($18.7B OCF vs $16.1B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Novo Nordisk A/S earns $30.34 in operating income for every $1 of interest expense ($20.1B vs $661.1M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
Novo Nordisk A/S generated $48.6B in revenue in fiscal year 2025. This represents an increase of 20.5% from the prior year.
Novo Nordisk A/S's EBITDA was $23.5B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 14.9% from the prior year.
Novo Nordisk A/S reported $16.1B in net income in fiscal year 2025. This represents an increase of 14.8% from the prior year.
Novo Nordisk A/S earned $3.62 per diluted share (EPS) in fiscal year 2025. This represents an increase of 15.2% from the prior year.
Cash & Balance Sheet
Novo Nordisk A/S generated $9.3B in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 9.6% from the prior year.
Novo Nordisk A/S held $4.2B in cash against $36.2B in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Novo Nordisk A/S's gross margin was 81.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 3.7 percentage points from the prior year.
Novo Nordisk A/S's operating margin was 41.3% in fiscal year 2025, reflecting core business profitability. This is down 2.9 percentage points from the prior year.
Novo Nordisk A/S's net profit margin was 33.1% in fiscal year 2025, showing the share of revenue converted to profit. This is down 1.6 percentage points from the prior year.
Novo Nordisk A/S's ROE was 52.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 17.6 percentage points from the prior year.
Capital Allocation
Novo Nordisk A/S invested $8.2B in research and development in fiscal year 2025. This represents an increase of 22.6% from the prior year.
Novo Nordisk A/S spent $218.1M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 92.2% from the prior year.
Novo Nordisk A/S invested $9.5B in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 44.4% from the prior year.
NVO Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $48.6B+20.5% | $40.3B+16.9% | $34.5B+35.4% | $25.5B+18.8% | $21.4B+2.7% | $20.9B+13.8% | $18.3B+6.8% | $17.2B-4.9% | $18.0B+13.7% | $15.9B+1.0% | $15.7B |
| Cost of Revenue | $9.2B+49.5% | $6.2B+16.4% | $5.3B+29.7% | $4.1B+13.7% | $3.6B+4.7% | $3.4B+14.0% | $3.0B+11.7% | $2.7B-5.0% | $2.8B+16.7% | $2.4B+3.5% | $2.4B |
| Gross Profit | $39.3B+15.2% | $34.1B+17.0% | $29.2B+36.5% | $21.4B+19.8% | $17.8B+2.3% | $17.4B+13.8% | $15.3B+5.9% | $14.5B-4.8% | $15.2B+13.1% | $13.4B+0.6% | $13.3B |
| R&D Expenses | $8.2B+22.6% | $6.7B+38.6% | $4.8B+39.2% | $3.5B+27.9% | $2.7B+6.4% | $2.5B+18.9% | $2.1B-5.9% | $2.3B+0.4% | $2.3B+9.5% | $2.1B+4.4% | $2.0B |
| Operating Income | $20.1B+12.6% | $17.8B+17.0% | $15.2B+41.4% | $10.8B+20.6% | $8.9B+0.3% | $8.9B+12.8% | $7.9B+8.8% | $7.2B-8.3% | $7.9B+15.0% | $6.9B-4.5% | $7.2B |
| EBITDA | $23.5B+14.9% | $20.5B+23.2% | $16.6B+40.6% | $11.8B+20.1% | $9.8B0.0% | $9.8B+12.7% | $8.7B+11.3% | $7.9B-6.7% | $8.4B+14.9% | $7.3B-3.9% | $7.6B |
| Interest Expense | $661.1M+190.4% | $227.6M+183.0% | $80.4M+47.9% | $54.4M+23.6% | $44.0M-31.4% | $64.1M+93.9% | $33.1M+153.4% | $13.0M-10.2% | $14.5M+57.5% | $9.2M-5.4% | $9.7M |
| Income Tax | $4.4B+21.4% | $3.6B+16.8% | $3.1B+60.0% | $1.9B+13.0% | $1.7B-4.6% | $1.8B+25.2% | $1.4B+4.6% | $1.4B-19.0% | $1.7B+21.6% | $1.4B+11.7% | $1.3B |
| Net Income | $16.1B+14.8% | $14.0B+12.9% | $12.4B+55.5% | $8.0B+9.9% | $7.3B+4.9% | $6.9B+18.3% | $5.9B-1.3% | $5.9B-3.7% | $6.2B+14.4% | $5.4B+6.1% | $5.1B |
| EPS (Basic) | $3.62+15.2% | $3.15+13.6% | $2.77+57.1% | $1.76+11.4% | $1.58 | $2.97+20.3% | $2.47+0.7% | $2.45-1.6% | $2.49+17.0% | $2.13+7.8% | $1.97 |
| EPS (Diluted) | $3.62+15.2% | $3.14+13.7% | $2.76+57.2% | $1.76+11.4% | $1.58 | $2.96+20.3% | $2.46+0.7% | $2.44-1.6% | $2.48+17.0% | $2.12+7.9% | $1.97 |
| Diluted Shares (Avg) | 4.45B-0.3% | 4.46B-0.7% | 4.49B-1.1% | 4.54B-1.3% | 4.61B | 2.34B-1.6% | 2.38B-1.9% | 2.42B-2.2% | 2.48B-2.2% | 2.53B-1.7% | 2.58B |
Not reported in any period shown, so not listed: SG&A Expenses.
NVO Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $85.3B+32.0% | $64.6B+38.5% | $46.7B+34.5% | $34.7B+17.2% | $29.6B+24.3% | $23.8B+26.2% | $18.9B+11.0% | $17.0B+2.8% | $16.5B+19.4% | $13.8B+3.6% | $13.4B |
| Current Assets | $27.1B+20.7% | $22.5B+8.4% | $20.7B+33.1% | $15.6B+19.5% | $13.0B+20.4% | $10.8B+15.3% | $9.4B+3.5% | $9.1B-6.6% | $9.7B+14.4% | $8.5B | N/A |
| Cash & Equivalents | $4.2B+91.4% | $2.2B+1.7% | $2.1B+17.3% | $1.8B+11.6% | $1.6B-18.8% | $2.0B-13.2% | $2.3B-3.4% | $2.4B-13.4% | $2.8B+5.7% | $2.6B+13.6% | $2.3B |
| Inventory | $7.8B+37.5% | $5.7B+20.1% | $4.7B+34.6% | $3.5B+17.5% | $3.0B-2.0% | $3.0B+14.9% | $2.7B+5.7% | $2.5B+1.0% | $2.5B+22.0% | $2.0B | N/A |
| Goodwill | $3.1B+12.2% | $2.8B | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $54.8B+22.6% | $44.7B+44.9% | $30.9B+35.9% | $22.7B+20.5% | $18.8B+40.4% | $13.4B+31.2% | $10.2B+13.0% | $9.0B+6.6% | $8.5B+14.4% | $7.4B+13.7% | $6.5B |
| Current Liabilities | $33.9B+12.2% | $30.2B+20.0% | $25.2B+44.7% | $17.4B+14.9% | $15.1B+31.1% | $11.6B+30.3% | $8.9B+6.6% | $8.3B+9.4% | $7.6B+12.9% | $6.7B | N/A |
| Non-Current Liabilities | $20.9B+44.3% | $14.5B+155.5% | $5.7B+7.2% | $5.3B+43.6% | $3.7B+98.3% | $1.9B+37.1% | $1.4B+85.7% | $731.3M-17.4% | $885.5M+29.1% | $686.0M | N/A |
| Long-Term Debt | $36.2B+91.1% | $18.9B+249.7% | $5.4B-16.5% | $6.5B+88.5% | $3.4B+622.8% | $476.2M+5.3% | $452.1Mn/m | $0 | N/A | N/A | N/A |
| Total Equity | $30.5B+53.1% | $19.9B+25.9% | $15.8B+31.7% | $12.0B+11.5% | $10.8B+3.4% | $10.4B+20.3% | $8.7B+8.8% | $8.0B-1.1% | $8.0B+25.2% | $6.4B-6.0% | $6.8B |
| Retained Earnings | $30.7B+53.1% | $20.0B+28.9% | $15.6B+34.2% | $11.6B+5.8% | $11.0B+4.5% | $10.5B+20.7% | $8.7B+6.0% | $8.2B+3.6% | $7.9B+20.8% | $6.5B | N/A |
Not reported in any period shown, so not listed: Short-Term Investments, Accounts Receivable, Long-Term Investments.
NVO Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $18.7B+11.5% | $16.8B+3.9% | $16.2B+42.4% | $11.3B+35.6% | $8.4B-2.0% | $8.5B+21.5% | $7.0B+2.7% | $6.8B+3.0% | $6.6B-3.1% | $6.9B+23.1% | $5.6B |
| Depreciation & Amortization | $3.5B+30.2% | $2.7B+89.9% | $1.4B+31.9% | $1.1B+15.5% | $917.0M-3.0% | $945.6M+11.2% | $850.6M+41.2% | $602.3M+17.2% | $513.8M+13.4% | $453.2M+5.2% | $430.6M |
| Capital Expenditures | $9.5B+44.4% | $6.5B+70.9% | $3.8B+119.2% | $1.7B+81.2% | $964.2M+0.7% | $957.4M-28.7% | $1.3B-9.2% | $1.5B+20.1% | $1.2B+22.8% | $1.0B+32.0% | $760.2M |
| Free Cash Flow | $9.3B-9.6% | $10.2B-16.9% | $12.3B+28.4% | $9.6B+29.6% | $7.4B-2.3% | $7.6B+33.3% | $5.7B+6.0% | $5.4B-0.9% | $5.4B-7.5% | $5.9B+21.7% | $4.8B |
| Investing Cash Flow | -$12.4Bn/m | -$17.9Bn/m | -$6.5Bn/m | -$3.6Bn/m | -$4.8Bn/m | -$3.7Bn/m | -$1.7Bn/m | -$1.9Bn/m | -$1.1Bn/m | -$963.6Mn/m | -$887.3M |
| Financing Cash Flow | -$4.5B-468.2% | $1.2Bn/m | -$9.4Bn/m | -$7.5Bn/m | -$3.9Bn/m | -$5.3Bn/m | -$5.3Bn/m | -$5.3Bn/m | -$5.8Bn/m | -$5.5Bn/m | -$4.4B |
| Dividends Paid | $8.1B+32.8% | $6.1B+30.0% | $4.7B+29.5% | $3.6B+11.2% | $3.3B-1.0% | $3.3B+13.4% | $2.9B-0.2% | $2.9B-3.9% | $3.0B-10.0% | $3.4B+80.1% | $1.9B |
| Share Buybacks | $218.1M-92.2% | $2.8B-36.9% | $4.4B+28.2% | $3.5B+17.1% | $3.0B+6.8% | $2.8B+20.2% | $2.3B-3.5% | $2.4B-12.2% | $2.7B+27.3% | $2.1B-14.8% | $2.5B |
Not reported in any period shown, so not listed: Stock-Based Compensation.
NVO Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 81.0%-3.7pp | 84.7%+0.1pp | 84.6%+0.7pp | 83.9%+0.7pp | 83.2%-0.3pp | 83.5%0.0pp | 83.5%-0.7pp | 84.3%0.0pp | 84.2%-0.4pp | 84.6%-0.4pp | 85.0% |
| Operating Margin | 41.3%-2.9pp | 44.2%0.0pp | 44.2%+1.9pp | 42.3%+0.6pp | 41.6%-1.0pp | 42.6%-0.4pp | 43.0%+0.8pp | 42.3%-1.6pp | 43.8%+0.5pp | 43.3%-2.5pp | 45.8% |
| Net Margin | 33.1%-1.6pp | 34.8%-1.3pp | 36.0%+4.6pp | 31.4%-2.5pp | 33.9%+0.7pp | 33.2%+1.3pp | 31.9%-2.6pp | 34.5%+0.4pp | 34.1%+0.2pp | 33.9%+1.6pp | 32.3% |
| Return on Equity | 52.8%-17.6pp | 70.4%-8.2pp | 78.5%+12.0pp | 66.5%-1.0pp | 67.5%+1.0pp | 66.5%-1.1pp | 67.6%-6.9pp | 74.5%-2.0pp | 76.5%-7.2pp | 83.8%+9.6pp | 74.2% |
| Return on Assets | 18.9%-2.8pp | 21.7%-4.9pp | 26.6%+3.6pp | 23.0%-1.5pp | 24.6%-4.5pp | 29.1%-1.9pp | 31.0%-3.9pp | 34.9%-2.4pp | 37.3%-1.6pp | 38.9%+0.9pp | 38.0% |
| Current Ratio | 0.80+0.1x | 0.74-0.1x | 0.82-0.1x | 0.890.0x | 0.86-0.1x | 0.94-0.1x | 1.060.0x | 1.09-0.2x | 1.280.0x | 1.26 | N/A |
| Debt-to-Equity | 1.19+0.2x | 0.95+0.6x | 0.34-0.2x | 0.54+0.2x | 0.32+0.3x | 0.050.0x | 0.05+0.1x | 0.00 | N/A | N/A | N/A |
| Liabilities-to-Equity | 1.80-0.4x | 2.25+0.3x | 1.95+0.1x | 1.89+0.1x | 1.75+0.5x | 1.29+0.1x | 1.180.0x | 1.14+0.1x | 1.05-0.1x | 1.15+0.2x | 0.95 |
| Asset Turnover | 0.57-0.1x | 0.62-0.1x | 0.740.0x | 0.730.0x | 0.72-0.2x | 0.88-0.1x | 0.970.0x | 1.01-0.1x | 1.09-0.1x | 1.150.0x | 1.18 |
| FCF Margin | 19.1%-6.3pp | 25.4%-10.4pp | 35.8%-1.9pp | 37.7%+3.2pp | 34.6%-1.8pp | 36.3%+5.3pp | 31.0%-0.3pp | 31.3%+1.3pp | 30.0%-6.9pp | 36.9%+6.3pp | 30.6% |
Note: The current ratio is below 1.0 (0.80), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Novo Nordisk A/S NVO | FY2025 | $48.6B | $16.1B | 33.1% | $172.6B | 69/100 |
| AstraZeneca PLC AZN | FY2025 | $58.7B | $10.2B | 17.4% | $270.5B | 61/100 |
| Novartis AG NVS | FY2025 | $56.7B | $14.0B | 24.7% | $304.3B | 68/100 |
| Merck & Co., Inc. MRK | FY2025 | $65.0B | $18.3B | 28.1% | $361.0B | 64/100 |
| AbbVie Inc. ABBV | FY2025 | $61.2B | $4.2B | 6.9% | $514.2B | 57/100 |
| Johnson & Johnson JNJ | FY2025 | $94.2B | $26.8B | 28.5% | $662.5B | 65/100 |
Where Novo Nordisk A/S Ranks
Frequently Asked Questions
What is Novo Nordisk A/S's annual revenue?
Novo Nordisk A/S (NVO) reported $48.6B in total revenue for fiscal year 2025. This represents a 20.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Novo Nordisk A/S's revenue growing?
Novo Nordisk A/S (NVO) revenue grew by 20.5% year-over-year, from $40.3B to $48.6B in fiscal year 2025.
Is Novo Nordisk A/S profitable?
Yes, Novo Nordisk A/S (NVO) reported a net income of $16.1B in fiscal year 2025, with a net profit margin of 33.1%.
What is Novo Nordisk A/S's EBITDA?
Novo Nordisk A/S (NVO) had EBITDA of $23.5B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Novo Nordisk A/S have?
As of fiscal year 2025, Novo Nordisk A/S (NVO) had $4.2B in cash and equivalents against $36.2B in long-term debt.
What is Novo Nordisk A/S's gross margin?
Novo Nordisk A/S (NVO) had a gross margin of 81.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Novo Nordisk A/S's operating margin?
Novo Nordisk A/S (NVO) had an operating margin of 41.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Novo Nordisk A/S's net profit margin?
Novo Nordisk A/S (NVO) had a net profit margin of 33.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Novo Nordisk A/S's return on equity (ROE)?
Novo Nordisk A/S (NVO) has a return on equity of 52.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Novo Nordisk A/S's free cash flow?
Novo Nordisk A/S (NVO) generated $9.3B in free cash flow during fiscal year 2025. This represents a -9.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Novo Nordisk A/S's operating cash flow?
Novo Nordisk A/S (NVO) generated $18.7B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Novo Nordisk A/S's total assets?
Novo Nordisk A/S (NVO) had $85.3B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Novo Nordisk A/S's capital expenditures?
Novo Nordisk A/S (NVO) invested $9.5B in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Novo Nordisk A/S spend on research and development?
Novo Nordisk A/S (NVO) invested $8.2B in research and development during fiscal year 2025.
What is Novo Nordisk A/S's current ratio?
Novo Nordisk A/S (NVO) had a current ratio of 0.80 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Novo Nordisk A/S's debt-to-equity ratio?
Novo Nordisk A/S (NVO) had a debt-to-equity ratio of 1.19 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
What is Novo Nordisk A/S's liabilities-to-equity ratio?
Novo Nordisk A/S (NVO) had a liabilities-to-equity ratio of 1.80 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
What is Novo Nordisk A/S's return on assets (ROA)?
Novo Nordisk A/S (NVO) had a return on assets of 18.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Novo Nordisk A/S's P/E ratio?
Novo Nordisk A/S (NVO) trades at 10.7x earnings, its market capitalization divided by $16.1B net income, FY2025. The market capitalization is $172.6B as of Oct 29, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Novo Nordisk A/S's price-to-sales ratio?
Novo Nordisk A/S (NVO) trades at 3.6x sales, its market capitalization divided by $48.6B revenue, FY2025. The market capitalization is $172.6B as of Oct 29, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Novo Nordisk A/S's Altman Z-Score?
Novo Nordisk A/S (NVO) has an Altman Z-Score of 3.64, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Novo Nordisk A/S's Piotroski F-Score?
Novo Nordisk A/S (NVO) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Novo Nordisk A/S's earnings high quality?
Novo Nordisk A/S (NVO) has an earnings quality ratio of 1.16x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Novo Nordisk A/S cover its interest payments?
Novo Nordisk A/S (NVO) has an interest coverage ratio of 30.34x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Novo Nordisk A/S?
Novo Nordisk A/S (NVO) scores 69 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.